MedTrace Logo

Studies of Hereditary Hemorrhagic Telangiectasia

NCT00004648 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2005-06-24

No results posted yet for this study

Summary

OBJECTIVES: I. Examine screening modalities for pulmonary vascular arteriovenous malformation (PAVM) in individuals with endoglin mutations.

II. Examine the prevalence of cerebral arteriovenous malformations (CAVM) in individuals with hereditary hemorrhagic telangiectasia (HHT).

III. Investigate whether modifier genes exist that determine which individuals with HHT due to an endoglin mutation develop PAVMs and which develop CAVMs.

IV. Investigate the frequency of cardiac valve abnormalities in individuals affected with HHT due to an endoglin mutations.

Conditions

  • Telangiectasia, Hereditary Hemorrhagic

Sponsors & Collaborators

  • University of Vermont

    collaborator OTHER

  • National Center for Research Resources (NCRR)

    lead NIH

Principal Investigators

  • Alan Guttmacher · University of Vermont

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004648 on ClinicalTrials.gov